anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this comprehensive case report, we examine a 29-year-old male who suffered a high-energy vehicular accident, resulting in a type III Hawkins fracture of the talus. This specific fracture type is critically associated with a greater than 90% risk of progressing to avascular necrosis (AVN) of the talus, a severe and debilitating condition. Alongside this, the patient sustained fractures of the medial and lateral malleolus. Due to extensive swelling and severe circulatory disorders, an immediate emergency surgical procedure was necessitated, employing nail fixation as a stabilizing intervention. Over the course of 12 months following the surgery, despite routine post-operative imaging including X-rays and computed tomography (CT) scans, the patient continued to experience significant pain and impairment. This condition led to further investigations, culminating in a magnetic resonance imaging (MRI) that revealed an area of 19.8∕20.9 mm of AVN on the talus dome's upper-lateral facet. Interestingly, earlier CT scans had indicated multiple osteitic lesions, but these findings lacked a clear clinical correspondence, presenting a diagnostic challenge. To resolve this ambiguity and to definitively distinguish between necrosis and infection, a targeted histopathological analysis was deemed necessary. This analysis was conducted on a bone fragment extracted during a follow-up surgical procedure for nail removal. The results from this analysis present an area of bone and myeloid tissue necrosis unequivocally confirming the presence of AVN, effectively ruling out osteitis as a potential diagnosis. This critical diagnostic clarification allowed for a shift in therapeutic strategy, enabling the initiation of a more focused and potentially curative treatment regimen.
PROBLEM TO BE SOLVED: To obtain the subject pharmaceutical preparation which has excellent antiallergic effect with low toxicity and can become a component of an antiallergic food product by using an extract of peels of mangosteen fruits with a polar solvent. SOLUTION: This pharmaceutical preparation contains an extract of fruit peels of mangosteen (Garcinia mangostana L.) as an active ingredient. From this extract, α-mangosteen whose R is methyl in the formula and γ-mangosteen whose R is H can be obtained. This extract is obtained by extracting the fracture or powder of fruit peels of mangosteen with a polar solvent, preferably methanol or ethanol. This extract can be expected to be utilized as a medicine for treatment of allergies, for example, mammalian poloinosis, hay fever, allergic rhinitis, asthma atopic dermatitis or conjunctivitis. In addition, this active ingredient can be formulated to food products to produce antiallergic food products.
SIGNIFICANCE STATEMENT: Proteinuria predicts accelerated decline in kidney function in CKD. The pathologic mechanisms are not well known, but aberrantly filtered proteins with enzymatic activity might be involved. The urokinase-type plasminogen activator (uPA)-plasminogen cascade activates complement and generates C3a and C5a in vitro / ex vivo in urine from healthy persons when exogenous, inactive, plasminogen, and complement factors are added. Amiloride inhibits uPA and attenuates complement activation in vitro and in vivo . In conditional podocin knockout (KO) mice with severe proteinuria, blocking of uPA with monoclonal antibodies significantly reduces the urine excretion of C3a and C5a and lowers tissue NLRP3-inflammasome protein without major changes in early fibrosis markers. This mechanism provides a link to proinflammatory signaling in proteinuria with possible long-term consequences for kidney function.
BACKGROUND: Persistent proteinuria is associated with tubular interstitial inflammation and predicts progressive kidney injury. In proteinuria, plasminogen is aberrantly filtered and activated by urokinase-type plasminogen activator (uPA), which promotes kidney fibrosis. We hypothesized that plasmin activates filtered complement factors C3 and C5 directly in tubular fluid, generating anaphylatoxins, and that this is attenuated by amiloride, an off-target uPA inhibitor.
METHODS: Purified C3, C5, plasminogen, urokinase, and urine from healthy humans were used for in vitro / ex vivo studies. Complement activation was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, immunoblotting, and ELISA. Urine and plasma from patients with diabetic nephropathy treated with high-dose amiloride and from mice with proteinuria (podocin knockout [KO]) treated with amiloride or inhibitory anti-uPA antibodies were analyzed.
RESULTS: The combination of uPA and plasminogen generated anaphylatoxins C3a and C5a from intact C3 and C5 and was inhibited by amiloride. Addition of exogenous plasminogen was sufficient for urine from healthy humans to activate complement. Conditional podocin KO in mice led to severe proteinuria and C3a and C5a urine excretion, which was attenuated reversibly by amiloride treatment for 4 days and reduced by >50% by inhibitory anti-uPA antibodies without altering proteinuria. NOD-, LRR- and pyrin domain-containing protein 3-inflammasome protein was reduced with no concomitant effect on fibrosis. In patients with diabetic nephropathy, amiloride reduced urinary excretion of C3dg and sC5b-9 significantly.
CONCLUSIONS: In conditions with proteinuria, uPA-plasmin generates anaphylatoxins in tubular fluid and promotes downstream complement activation sensitive to amiloride. This mechanism links proteinuria to intratubular proinflammatory signaling. In perspective, amiloride could exert reno-protective effects beyond natriuresis and BP reduction.
CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease, NCT01918488 and Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients, NCT03036748 .
NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening.
A medical image processing device such as an ultrasonic diagnosis device, wherein an observation point tracking process is sequentially performed between each of the adjacent frames in a frame sequence. The observation point thereby moves from the start coordinates to the end coordinates in a single heartbeat period. The difference between the coordinates is the error vector, and the total correction amount is obtained from the error vector. The total correction amount is adaptively allocated to individual frames to be corrected in the expansion period. More specifically, the allocated amount for each of the frames to be corrected is calculated on the basis of the amount of movement of the observation point representing the error indicator value obtained for each of the frames to be corrected. A larger allocation amount is applied for a larger amount of observation point movement, and a smaller allocation amount is applied for a smaller amount of observation point movement. It is thereby possible to naturally correct each of the observation point coordinates.
Checkpoint inhibitor naive subjects during the treatment phase will receive IV infusion of pembrolizumab at 200 mg for adults (≥ 18 years of age) or 2 mg/kg for adolescents (12 to \< 18 years of age) prior to the administration of tabelecleucel on Day 1; and IV infusion of tabelecleucel (tab-cel) at 2 × 10\^6 T-cells/kg on Days 1, 8, and 15 of each 21-day treatment/consolidation cycles (at least 2 cycles or up to 4 cycles). From the Maintenance Phase, subjects with stable disease or better will receive tabelecleucel on Day 1 and pembrolizumab on Day 1, Day 21, Day 42, and Day 63 of each 84- day maintenance cycle, which was continued until disease progression, unacceptable toxicity, or a total of 35 pembrolizumab infusions (including for treatment, consolidation, and maintenance) had been administered, whichever occurred first.
Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
Bronchiectasis is still a common chronic respiratory disease. Non-cystic fibrosis bronchiectasis is characterized by irreversible dilatation of the medium-sized bronchi as a result of airway injury due to recurrent or chronic inflammation and infection. Clinical features of bronchiectasis include chronic production of sputum often mucopurulent or purulent in nature, persistent bacterial colonization, recurrent lower respiratory tract infections. Bronchiectasis airways are often colonized with bacterial species. Infections of the airways are thought to play an important role in bronchiectasis exacerbation. Progressive lung damage in bronchiectasis results from a 'vicious cycle' of recurrent bacterial infection and a deregulated inflammatory response. The non-specific prevention of recurrent airway infections by immunostimulating agents has gained growing scientific interest. OM-85, consisting extracts of eight kinds of bacteria important in respiratory infections, has been known to support the respiratory tract resistance to the pathogens via activating pulmonary macrophages, increasing the ratio of CD4 to CD8 lymphocytes, and changing the level of a variety of cytokines in the lung. OM-85 has shown the benefit for significantly reducing the incidence of exacerbations of chronic obstructive pulmonary disease (COPD). Bronchiectasis exacerbations contribute substantially to rapid decline in lung function, reduced quality of life, and the medical costs. The purpose of this study is to investigate the PReventive effect of OM-85 on Bronchiectasis Exacerbation in Chinese patients (iPROBE).

This study is designed as a prospective randomised double-blind placebo-controlled multi-centred trial. A total of 244 patients with bronchiectasis, who have had at least one exacerbation of bronchiectasis in the previous year, will be included. The subjects will be randomly received two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.

We will investigate whether long-term therapy with an oral immunostimulant OM-85 can decrease exacerbations in patients with bronchiectasis over 1-year period. Besides, we will assess other outcomes including: the rate of event-based exacerbation, lung function parameters, the total scores on the St George's respiratory questionnaire and coughing, and inflammatory index. We hope that this study will provide novel information on the preventive effects of OM-85 treatment on bronchiectasis exacerbation and will address a knowledge gap for this poorly understood and under-studied disease.
PROBLEM TO BE SOLVED: To obtain a ceramics capable of freely controlling its particle size or pore diameter, excellent in carrying property for a medicine, affinity to a live body, sustained release property for a medicine and absorption property for live body and useful as a bone filler and a sustained release carrier for medicine by dropping a ceramic material onto a low temp. medium to freeze-dry the material and then sintering. SOLUTION: The ceramics consisting preferably of calcium phosphate, more preferably of hydroxyapatite, tricalcium phosphate, calcium secondary phosphate, tetracalcium phosphate, octacalcium phosphate or the mixture thereof is pulverized, for example, preferably to <=100μm particle size. Then the ceramic material is mixed with a binder slurry (such as PVA soln.) and dropped onto a low temp. medium (such as liquid nitrogen) to freeze while its spherical shape is maintained. The frozen material is dried to remove the water content while preventing defrosting, and further sintered at 800 to 1,500 deg.C, preferably 1,000 to 1,400 deg.C.
FIELD: medicine, biochemistry. SUBSTANCE: extract is prepared from sapropel by three-fold volume of 0.1 M ammonium solution and extract is kept at -15 C for 24 h. After defrosting at the room temperature supernatant is decanted and concentrated by evaporation under vacuum. The concentrated fraction is centrifuged and dialyzed. Nondyalizable fraction is treated with ammonium sulfate at 100% degree of saturation and the formed precipitate is discarded. The purified fraction is desalted with 96% ethyl alcohol followed by gel-filtration on column with Sephadex G-50. Eluates are combined and dried. EFFECT: enhanced purity of end product. 1 tbl
Injectable nano micelles of anticancer agents which contain vinca alkaloids as the actives, namely Vinbastine, Vincrisitin, Vindesine, Vinorelbine, in a therapeutically effective amount, and polyethylene glycolylated phospholipids as well as pharmaceutically acceptable adjuvants. The manufacturing method comprises preparing the injectable nano micelles of vinca alkaloids by encapsuling them into pre-formed nano micelles. Vinca alkaloids and polyethylene glycol-derived phospholipids form the nano micelles of uniform particle size distribution. The polyethylene glycol molecules form a hydrophilic overlayer around the hydrophobic core of the loaded therapeutic agents. And this overlayer serves to protect the drugs of interest from the interaction with certain proteins in the blood, such as enzymes, and from being recognized and phagocytized by the internal reticuloendothelial system, which allow for achieving longevity in circulation in vivo. In addition, the micelles further increase the storage stability and efficacy against cancers with a lower toxicity.
NEW MATERIAL:A syn isomer of a compound expressed by formula I [R<1> is (protected) amino; R<2> is (protected)carboxyl] and a salt thereof. EXAMPLE:7-[ 2-( 2-Amiothiazol-4-yl )-2-hydroxyiminoacetamido ]-3-vinyl-3-cephem- 4-carboxylic acid (syn isomer). USE:An antimicrobial agent against Gram-positive and Gram-negative bacteria, etc. useful particularly for oral administration. PROCESS:A compound expressed by formula II (X is halogen) or a salt thereof is reacted with a compound expressed by formula III usually in an inert solvent, e.g. ethyl acetate, to give the compound expressed by formula I . The compound expressed by formula II is a novel substance, and can be obtained by reacting a compound expressed by formula IV with a compound expressed by the formula X-CH2COCH2COOH to form a compound expressed by formula V, and reacting the resultant compound expressed by formula V with a nitrosating agent.
The invention discloses a production technology of prepared fleeceflower root. The production technology of the prepared fleeceflower root comprises the steps of choosing, washing, moistening, cutting, stewing, vacuum-freezing and drying, screening, packaging and the like. The fleeceflower root is soaked and infiltrated by an HQG-3-type rotary infiltration tank. Compared with the traditional common soaking and softening modes, the softening time of the crude drugs is greatly shortened; the production efficiency is improved; the effective ingredients of the crude drugs are preserved to the maximal extent; and the product quality is improved. The juice prepared from radix rehmanniae preparata, mulberry, medlar and yellow wine is used for cooking the fleeceflower root, and thus, the functional nutrient of the fleeceflower root can be improved; and the cooked decoction is used for stirring the fleeceflower root, so that the loss of the effective ingredients can be reduced. The production technology disclosed by the invention is simple and easy to operate, scientific and reasonable, and good in controllability; the produced processed fleeceflower root slice is good in character, high in keratinization degree, less in disintegrating slag, and compact in structure; the quality of the fleeceflower root slice is improved; and the fleeceflower root slice is suitable for drinking of all people.
Deterioration of kidney function after orthotopic liver transplantation is a common complication that may occur after perioperative acute kidney injury (AKI) and preexisting or developing chronic kidney disease (CKD). AKI is described in the early postoperative period in more than half of recipients, whereas the main cause of CKD is pharmacotherapy. When end-stage renal failure occurs, patients may be qualified for additional transplantations. We present a rare case of a 27-year-old woman who, as a teenager, underwent 2 liver transplantations due to Wilson's disease. Surgeries were complicated by systemic infection and multiple organ failure. The kidneys did not regain their function, and therefore, after 6 months of dialysis, the organ was transplanted. Three organ transplantations were performed. Due to the patient's willingness and good graft functions, the patient started trying to conceive. Three months before successful conception, immunosuppressive therapy was changed to tacrolimus and azathioprine. Pregnancy was complicated by pregnancy-induced hypertension, and its course was closely monitored. Organ functions and immunosuppressive therapy were regularly assessed. Due to the pre-eclampsia developed in the 35th week of gestation, a Cesarean delivery was performed, and she gave birth to a daughter weighing 2350 g (Apgar 7-7-8). The patient decided to breastfeed. There were no obstetric complications or graft function deterioration in the early postpartum period. Mother and daughter left home after 7 days of hospitalization. The presented clinical situation proves that multiorgan transplantation recipients can have a successful pregnancy without impairing graft functions. Therefore, the pregnancy requires adequate preparation and increased care.
The invention relates to a compound medicine for slimming and grease removal and a preparation method thereof. The invention is characterized in that the medicine is prepared from selected Chinese medicinal herb essence components with reasonable compatibility by a special technique. The medicine is prepared from pure Chinese medicinal herb components and is free of any chemical component. The Chinese medicinal herb components are strictly screened and proportioned through the experiments, so the medicine has favorable compound effect. The medicine is prepared by a special technique, has the advantages of stable quality and no toxic or side effect on the human body, is convenient to take, and is used for treating obesity caused by vigorous stomach fire and more excrement with less intake. The medicine is suitable for wind heat congestions, such as conjunctival congestion, nasal obstruction, dry mouth, cough, inhibited throat, constipation, scanty dark urine, obesity and the like, and has the actions of eliminating pathogenic heat, discharging stubborn scales and strengthening the body for patients with solid exterior-interior triple energizers.
PCT No. PCT/US95/01469 Sec. 371 Date Nov. 26, 1996 Sec. 102(e) Date Nov. 26, 1996 PCT Filed Feb. 3, 1995 PCT Pub. No. WO95/21245 PCT Pub. Date Aug. 10, 1995The present invention pertains to a method for delivering a neuropharmaceutical agent across the blood brain barrier to the brain of a host. The method comprises administering to the host a therapeutically effective amount of a ligand-neuropharmaceutical agent fusion protein wherein the ligand is reactive with a brain capillary endothelial cell receptor. Other aspects of this invention include a delivery system comprising a ligand reactive with a brain capillary endothelial cell receptor which has formed a fusion protein with a neuropharmaceutical agent. The fusion proteins are also aspects of this invention.
Invasive adenocarcinoma is a malignant epithelial tumor with glandular differentiation, mucin production, or pneumocyte marker expression. The tumors show an acinar, papillary, micropapillary, lepidic, or solid growth pattern, with either mucin or pneumocyte marker expression. The invasive ademocarcinoma component should be present in at least one focus measuring \>5mm in greatest dimension.
Intrauterine growth restriction significantly impacts perinatal outcomes. Undetected IUGR escalates the risk of adverse outcomes. Serial symphysis-fundal height measurement, a recommended strategy, is insufficient in detecting abnormal fetal growth. Routine third-trimester ultrasounds significantly improve detection rates compared with this approach, but direct high-quality evidence supporting enhanced perinatal outcomes from routine scanning is lacking. In assessing fetal growth, abdominal circumference alone performs comparably to estimated fetal weight. Hadlock formulas demonstrate accurate fetal weight estimation across diverse gestational ages and settings. When choosing growth charts, prescriptive standards (encompassing healthy pregnancies) should be prioritized over descriptive ones. Customized fetal standards may enhance antenatal IUGR detection, but conclusive high-quality evidence is elusive. Emerging observational data suggest that longitudinal fetal growth assessment could predict adverse outcomes better. However, direct randomized trial evidence supporting this remains insufficient.
IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).

Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age [see Contraindications (4), Warnings and Precautions (5.2), Use in Specific Populations (8.4)].
To establish a pathway for comparative effectiveness using patient reported outcomes in minimally invasive surgery, we propose to use a readily available and easily reproducible model: cholecystectomy. Each year in the United States, approximately 750,000 patients undergo a cholecystectomy. Patients clearly prefer the laparoscopic approach over the open procedure to abdominal surgery. Initial survey data suggest that patients may also prefer even less invasive approaches.

Currently, the standard operative procedure for a patient with symptomatic gallstone disease is a laparoscopic cholecystectomy performed under general anesthesia with four small abdominal incisions. Although postoperative pain and cardiopulmonary and wound complications are much less compared to open cholecystectomy, considerable cost is generated from lost productivity in days off of work after the surgical procedure related in part to pain and the physiologic response to the stress of the operative procedure. Anecdotal data suggest that fewer incisions, especially fewer transabdominal incisions, translate into less pain, less need for narcotic pain medication and faster recovery, but randomized trial data are needed. We propose to compare the effectiveness of the novel single-port cholecystectomy with laparoscopic cholecystectomy, the current standard of care.